4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Oruka Therapeutics, Inc. (ORKA) operates in the Biotechnology industry and is headquartered in Menlo Park, United States with about 68 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, ORKA reported $0M in revenue and ($105M) in net income.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Interactive charts & full statements →
| Income statement | 2025-12-31 |
|---|---|
| Total Revenue | $0M |
| Operating Income (EBIT) | ($122M) |
| Net Income | ($105M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($36M) | ($34M) | ($34M) | ($28M) | ($25M) |
| Net Income | ($32M) | ($30M) | ($30M) | ($25M) | ($21M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $489M | $396M |
| Total Liabilities | $20M | $17M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ORKA viewer.
About TickerBase · Data methodology & sources